Cue Biopharma, Inc.
Price Action
Technical Summary
EMERGING TRENDCue Biopharma, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings growth of 79% provides fundamental context to the price action. However, price is extended 22% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $27.43 | +10.94% | ABOVE |
| 50 SMA | $24.98 | +21.80% | ABOVE |
| 100 SMA | $17.08 | +78.19% | ABOVE |
| 150 SMA | $15.48 | +96.56% | ABOVE |
| 200 SMA | $17.09 | +78.04% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CUE in an uptrend right now?
CUE has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is CUE overbought or oversold?
CUE's RSI (14) is 49. The stock is in neutral territory, neither overbought nor oversold.
Is CUE outperforming the market?
CUE has a Relative Strength (RS) Rating of 96 out of 99. Yes, CUE is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is CUE in its 52-week range?
CUE is trading at $30.43, which is 73% of its 52-week high ($41.42) and 73% above its 52-week low ($0.35).
How volatile is CUE?
CUE has a Beta of 2.49 and 52-week volatility of 187%. It's more volatile than the S&P 500 - expect bigger swings.